Prenylisoflavonoids from Erythrina senegalensis as Novel HIV-1 Protease Inhibitors

被引：32

作者：

Lee, JiSuk ^{[1
,2
]}

Oh, Won Keun ^{[3
]}

Ahn, Jong Seog ^{[3
]}

Kim, Yong Hae ^{[4
]}

Mbafor, J. Tanyi ^{[5
]}

Wandji, Jean ^{[5
]}

Fomum, Z. Tanee ^{[5
]}

机构：

[1] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea

[2] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea

[3] KRIBB, Taejon, South Korea

[4] Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea

[5] Univ Yaounde, Dept Organ Chem, Yaounde, Cameroon

来源：

PLANTA MEDICA | 2009年 / 75卷 / 03期

关键词：

Erythrina senegalensis; Leguminosae; prenylated isoflavonoids; HIV-1; protease; PRENYLATED FLAVONOIDS; STEM BARK; MOGHANIA-PHILIPPINENSIS; CONSTITUENTS; 8-PRENYLLUTEONE; ISOFLAVONOIDS; ROOTS; SEEDS;

D O I：

10.1055/s-0028-1088395

中图分类号：

Q94 [植物学];

学科分类号：

071001 ;

摘要：

Eight compounds were isolated from the CH2Cl2 extracts of Erythrina senegalensis to assess HIV-1 protease (PR) activity inhibition. The prenylated isoflavone structures, identified by spectroscopic analysis, were 8-prenylluteone (1), auriculatin (2), erysenegalensein O (3), erysenegalensein D (4), erysenegalensein N (5), derrone (6), alpinumisoflavone (7), and 6,8-diprenylgenistein (8). The constituents showed dose-dependent inhibitory activities on HIV-1 PR with IC50 values from 0.5 to 30.0 mu M. Compounds 1-5 possessing two hydroxy groups in the 2' and 4' positions of the B ring, potently inhibited HIV-1 PR activity. In addition, 6,8-diprenylgenistein (8) with two prenyl groups in the 6 and 8 positions of the A ring and one hydroxy group in the 4' position of B-ring was the most potent HIV-1 PR inhibitor.

引用

页码：268 / 270

页数：3

共 50 条

[21] Resistance to HIV-1 protease inhibitors
Swanstrom, R
Smith, T
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 58 - BIOT
[22] HIV-1 protease and its inhibitors
Geller, M
Trylska, J
Antosiewicz, J
THEORETICAL AND COMPUTATIONAL METHODS IN GENOME RESEARCH, 1997, : 237 - 254
[23] AZIRIDINE INHIBITORS OF HIV-1 PROTEASE
LEVERETT, B
BAI, JC
POST, CB
LOUDON, GM
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1994, 208 : 37 - MEDI
[24] HIV-1 protease inhibitors and mechanisms of HIV-1's resistance
Das, Debananda
GLOBAL HEALTH & MEDICINE, 2024, 6 (06): : 357 - 362
[25] Peptides derived from HIV-1 Vif: A non-substrate based novel type of HIV-1 protease inhibitors
Friedler, A
Blumenzweig, I
Baraz, L
Steinitz, M
Kotler, M
Gilon, C
JOURNAL OF MOLECULAR BIOLOGY, 1999, 287 (01) : 93 - 101
[26] Towards the synthesis of novel boronates as potential HIV-1 protease inhibitors
Frank, Michael D.
Faulkner, Andrea L.
Jennings, Julia J.
Sigurjonsson, Kristin
Schreiber, John D.
Fabry-Asztalos, Levente
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
[27] Synthesis of novel borinic acids as potential HIV-1 protease inhibitors
Jia, Yinshan
Heer, Tajinder S.
Nguyen, David V.
O'Connell, Tracy K.
Fabry-Asztalos, Levente
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 56 - 56
[28] Synthesis of novel HIV-1 protease inhibitors based on carbohydrate scaffolds
Murphy, PV
O'Brien, JL
Gorey-Feret, LJ
Smith, AB
TETRAHEDRON, 2003, 59 (13) : 2259 - 2271
[29] Toward the synthesis of novel boronates as potential HIV-1 protease inhibitors
Contreras, Erik M.
Sigurjonsson, Kristin
Frank, Michael D.
Treich, Nicholas
Fabry-Asztalos, Levente
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
[30] Novel HIV-1 protease inhibitors: Design, synthesis, and biological evaluation
Osswald, Heather
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254

← 1 2 3 4 5 →